1 Research Article

2 Lumipulse G SARS-CoV-2 Ag Assay Evaluation for SARS-CoV-2 Antigen Detection Using

3 594 Nasopharyngeal Swab Samples from Different Testing Groups

Giulia Menchinelli^{a,b,§}, Licia Bordi^{c,§}, Flora Marzia Liotti^{a,b,§}, Ivana Palucci^{a,b}, Maria Rosaria
Capobianchi^c, Giuseppe Sberna^c, Eleonora Lalle^c, Lucio Romano^b, Giulia De Angelis^{a,b}, Simona
Marchetti^b, Maurizio Sanguinetti^{a,b,*}, Paola Cattani^{a,b,#}, and Brunella Posteraro^{a,d,#}

7

^aDipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie,
Università Cattolica del Sacro Cuore, Roma, Italy; ^bDipartimento di Scienze di Laboratorio e
Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; ^cIstituto
Nazionale per le Malattie Infettive (INMI) Lazzaro Spallanzani IRCCS, Rome, Italy; ^dDipartimento
di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma,
Italy

14

[§]The first three authors contributed equally to this work. Author order was determined randomly.

[#]The last two authors contributed equally to this work. Author order was decided alphabetically.

¹⁷ Corresponding author. E-mail: maurizio.sanguinetti@unicatt.it

18 **Running title:** SARS-CoV-2 Antigen Detection in Testing Groups

20 ABSTRACT

Compared to RT-PCR, lower performance of antigen detection assays, including the Lumipulse G 21 SARS-CoV-2 Ag assay, may depend on specific testing scenarios. We tested 594 nasopharyngeal 22 swab samples from individuals with COVID-19 (RT-PCR cycle threshold [Ct] values <40) or non-23 COVID-19 (Ct values ≤ 40) diagnoses. RT-PCR positive samples were assigned to diagnostic, 24 screening, or monitoring groups of testing. With a limit of detection of 1.2×10^4 SARS-CoV-2 25 RNA copies/ml, Lumipulse showed positive percent agreement (PPA) of 79.9% (155/194) and 26 negative percent agreement of 99.3% (397/400), whereas PPAs were 100% for samples with Ct 27 values of <18 or 18-<25 and 92.5% for samples with Ct values of 25-<30. By three groups, 28 29 Lumipulse showed PPA of 87.0% (60/69), 81.1% (43/53), or 72.2% (52/72), respectively, whereas PPA was 100% for samples with Ct values of <18 or 18-<25, and was 94.4%, 80.0%, or 100% for 30 samples with Ct values of 25-<30, respectively. RT-PCR positive samples were also tested for 31 32 SARS-CoV-2 subgenomic RNA and, by three groups, testing showed that PPA was 63.8% (44/69), 62.3% (33/53), or 33.3% (24/72), respectively. PPAs dropped to 55.6%, 20.0%, or 41.7% for 33 samples with Ct values of 25-<30, respectively. All 101 samples with a subgenomic RNA positive 34 result had a Lumipulse assay's antigen positive result, whereas only 54 (58.1%) of remaining 93 35 samples had a Lumipulse assay's antigen positive result. In conclusion, Lumipulse assay was highly 36 37 sensitive in samples with low RT-PCR Ct values, implying repeated testing to reduce consequences of false-negative results. 38

KEYWORDS antigen detection, Lumipulse assay, nasopharyngeal swab, SARS-CoV-2, testing
group

42 INTRODUCTION

Antigen testing has recently been added to the landscape of clinical laboratory methods to detect 43 and combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the 44 notorious cause of coronavirus disease 2019 (COVID-19) (https://www.cdc.gov/coronavirus/2019-45 ncov/lab/resources/antigen-tests-guidelines.html#anchor 1597523027400). Like the molecular-46 relying on real-time reverse-transcription polymerase chain reaction (RT-PCR) and, to date, the 47 standard method for the etiological COVID-19 diagnosis-antigen testing detects the presence of 48 SARS-CoV-2 in the acute infection phase only (1). Unlike the molecular or antigen, antibody 49 testing is relevant in the convalescent or recovered infection phases only (1). 50

Theoretically, antigen-based assays are advantageous in terms of fast turnaround times and 51 52 reduced costs but are less sensitive than RT-PCR-based assays (2). Additionally, the former have the disadvantage to provide false-positive results, which leads false-positive patients to be managed 53 as patients with true SARS-CoV-2 infection (3, 4). However, the false-positive result likelihood 54 seems to depend on specific testing scenarios (e.g., those to identify infected persons who are 55 asymptomatic without SARS-CoV-2) 56 and known or suspected exposure to (https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-57

guidelines.html#anchor_1597523027400). To mitigate this issue, the European Centre for Disease 58 59 Prevention and Control (ECDC) recommends antigen-based assays to be not only carefully selected but also validated before their implementation in clinical practice (5). Since June 2020, the 60 Lumipulse G SARS-CoV-2 Ag (Fujirebio, Tokyo, Japan), detecting SARS-CoV-2 nucleocapsid (N) 61 62 protein, is being used in Japan where, according to the Japanese Ministry of Health, Labour and Welfare policy (4), a positive antigen test result is enough to definitively diagnose COVID-19 63 without PCR—which is instead mandatory in European countries to confirm positive antigen results 64 (5). Two independent studies by Hirotsu et al. (6, 7) reported on the performance of the Lumipulse 65 G SARS-CoV-2 Ag assay (hereafter referred as the Lumipulse assay) using nasopharyngeal swab 66

samples. Serial or individual samples from 11 RT-PCR positive (SARS-CoV-2 infected) patients and 215 RT-PCR negative (SARS-CoV-2 uninfected) patients (6) or 27 serial samples from one patient with persistent SARS-CoV-2 RNA shedding during hospitalization (7) were used. In both studies, samples with high viral load (corresponding to low values of RT-PCR cycle threshold [Ct]—an accredited measure of virus [5]) or samples collected in the early infection phase showed complete concordance between Lumipulse and RT-PCR results.

With the aim to fully understanding its usefulness, we evaluated the Lumipulse assay with 594 individuals' nasopharyngeal swab samples assigned to different testing groups (i.e., including early or late infection patients). To this end, we compared Lumipulse assay antigen results with those of RT-PCR assay targeting SARS-CoV-2 genomic RNA (usually used as an indicator of viral presence). In parallel, RT-PCR positive samples were analyzed for the presence of subgenomic RNA (recently proposed as an indicator of active viral replication) to support Lumipulse assay' results.

81 MATERIALS AND METHODS

Study design and clinical samples. This study was conducted at the Fondazione Policlinico 82 Universitario A. Gemelli IRCCS (FPG) and was approved by the FPG Ethics Committee (reference 83 number 49978/20). Informed consent was obtained from all participants before including their 84 samples in the study. We included nasopharyngeal swab samples from patients/individuals (≥ 18 -85 year aged) presenting at and/or admitted to our institution during a 2-week period in December 86 2020. Samples were from laboratory-confirmed COVID-19 (n = 194) or non-COVID-19 (n = 400) 87 diagnoses, which relied, respectively, on positive (Ct values of ≤ 40) or negative (Ct values of >40) 88 results obtained using the Seegene Allplex 2019-nCoV, the DiaSorin Simplexa COVID-19 Direct, 89 90 or the Roche Diagnostics Cobas SARS-CoV-2 Test RT-PCR assays (8-10). For example, the Seegene Allplex 2019-nCoV assay is a single-tube assay targeting the envelope (E), RdRP (RNA-91 dependent RNA polymerase), and N SARS-CoV-2 genes and running on a Bio-Rad CFX96 Real-92 time Detection system. Based on Ct values-i.e., numbers of cycles the fluorescent signal crosses 93 the threshold for positive detections—the Seegene software automatically analyzes RT-PCR results. 94 By this assay, a Ct value ≤40 for at least one of two viral genes (i.e., RdRP and N) or for the E gene 95 alone indicates, respectively, the certain or presumptive presence of SARS-CoV-2 RNA in the 96 97 sample. No positive samples only for E gene were included in the study. In view of relatively lower 98 performance of the DiaSorin Simplexa COVID-19 Direct assay (8, 11), samples (n = 39) initially tested with this assay were retested with the Seegene Allplex 2019-nCoV assay to confirm 99 (positive) results. Likewise, samples with discordant results between the RT-PCR and the 100 101 Lumipulse assays (see below) were confirmed as positive (n = 39) or negative (n = 3) by retesting as previously described (12). 102

For stratification purposes (5), we selected positive samples based on their Ct values (i.e., 11.2– 39.9) to include samples with different viral load levels. These samples were characterized for the inclusion in three testing groups, namely diagnostic, screening, and monitoring groups, which were

in substantial accordance with the definitions reported in the interim technical guidance by the
 Centers for Disease Control and Prevention (CDC) for rapid SARS-CoV-2 antigen testing
 (https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-

guidelines.html#anchor_1597523027400). Accordingly, diagnostic or monitoring groups included persons who had signs or symptoms (i.e., clinical illness) consistent with COVID-19, who had no clinical illness but a recent known or suspected exposure to SARS-CoV-2, or who had a previous laboratory-confirmed COVID-19 diagnosis, whereas the screening group included persons who were asymptomatic and without known or suspected exposure to SARS-CoV-2. All positive samples were further stratified in five groups based on RT-PCR Ct values (<18, 18–<25, 25–<30, 30–<35, and 35–40).</p>

All samples originally collected into universal transport medium (UTM; Copan, Brescia, Italy) were portioned in aliquots that were kept at 4°C until testing with the Lumipulse assay (see below), which was always performed within 2–4 hours from the time samples were subjected to RT-PCR for detecting SARS-CoV-2 genomic RNA as above described. In parallel, additional aliquots from the same samples were frozen at -80°C until testing for SARS-CoV-2 subgenomic RNA (see below). Furthermore, we used archived frozen samples (RT-PCR negative) as a matrix to generate contrived samples for the Lumipulse assay's analytical sensitivity determination (see below).

123 Lumipulse assay for SARS-CoV-2 antigen detection. The Lumipulse assay quantitatively detects SARS-CoV-2 N protein in clinical samples (e.g., nasopharyngeal swab) by a specific two-reaction 124 chemiluminescence-based immunoassay method on the Lumipulse G1200 automated immunoassay 125 126 analyzer (Fujirebio). In the first reaction, the sample (or the SARS-CoV-2 Ag calibrator) and the sample treatment solution are added to an anti-SARS-CoV-2 monoclonal antibody-coated magnetic 127 particle solution, and then incubated for 10 min at 37°C to allow formation of specific antigen-128 antibody immunocomplexes. In the second reaction (accessed after washing), an alkaline 129 phosphatase-labelled anti-SARS-CoV-2 monoclonal antibody solution is added and incubated for 130

10 min at 37°C to allow specific binding to the antigen of aforementioned immunocomplexes, and 132 then to form additional immunocomplexes. Finally (after washing), a substrate solution is added 133 and incubated for 5 min at 37°C, and the resulting chemiluminescence signals are automatically 134 read by the analyzer and used to calculate the SARS-CoV-2 antigen's amount in the sample through 135 the interpolation with a SARS-CoV-2 Ag calibrator curve.

We determined the limit of detection (LOD) of the Lumipulse assay according to a previously 136 described protocol (9). Briefly, aforementioned contrived samples were spiked with a dilution series 137 of Vero E6 cell-cultured SARS-CoV-2 (INMI-1 strain) at a concentration range of 1.0×10^5 50% 138 tissue culture infective dose (TCID₅₀)/ml (4.0×10^8 RNA copies/ml) to 1.0 TCID₅₀/ml (4.0×10^3 139 140 RNA copies/ml), and then tested in replicates (Fig. S1). For each sample, SARS-CoV-2 RNA was amplified by RT-PCR in Rotor-GeneQ Real-Time cycler (Qiagen, Hilden, Germany), using the 141 RealStar SARS-CoV-2 RT-PCR kit 1.0 (Altona Diagnostic GmbH, Hamburg, Germany). RNA 142 copies/ml were calculated through a standard curve prepared with serially diluted EURM-019 143 single-strand SARS-CoV-2 RNA fragments (https://crm.jrc.ec.europa.eu/p/EURM-019). Thus, we 144 plotted the probability (y-axis) against the SARS-CoV-2 concentration's logarithm (x-axis), and we 145 calculated the 95% LOD value, which was the lowest concentration at which the replicates yielded 146 positive detection 95% of the time (Fig. S1). 147

Before testing with the Lumipulse assay, samples were centrifuged at $3000 \times g$ for 15 min to allow 148 separation of the supernatant from the remaining viscous UTM material, and 100 µl were analyzed 149 for the antigen quantification as above described. Samples with an antigen level exceeding the 150 detection limit (i.e., 5000 pg/ml) were diluted, and dilutions were used to quantify the original 151 samples' antigen levels based on the dilution factor. Results were interpreted using a cutoff of 1.34 152 pg/ml as established by the Lumipulse assay's manufacturer, and were expressed as negative (<1.34 153 pg/ml), gray-zone positive (1.34–10 pg/ml), or positive (>10->5000) results, respectively. For 154 convenience reasons, antigen concentrations >5000 pg/ml were rounded to 5000 pg/ml. 155

RT-PCR assay for SARS-CoV-2 subgenomic RNA detection. To determine the presence of 156 SARS-CoV-2 subgenomic RNA (i.e., E gene subgenomic RNA), samples were subjected to a 157 previously developed in-house RT-PCR assay (13). This is an adaptation from the method described 158 by Wölfel et al. (14) that looks specifically at the E gene subgenomic RNA to indicate active virus 159 infection/transcription (15). Briefly, SARS-CoV-2 RNA (also including genomic RNA) was 160 extracted from samples using the Seegene Nimbus automated system and then used for the RT-PCR 161 assay. This was performed with the Qiagen OneStep RT-PCR kit (Qiagen, Valencia, CA) and a 25-162 µl reaction volume containing 600 nM concentration each of primers (sgE SARS-CoV2 F 5'-163 CGATCTCTTGTAGATCTGTTCTC-3'; sgE SARS-CoV2 R 5'-164 ATATTGCAGCAGTACGCACACA-3') and 200 nM concentration of probe (sgE SARS-CoV2 P 165 5'-FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ-3'). Thermal cycling consisted of 30 166 min at 50°C for reverse transcription, followed by 15 min at 95°C and subsequent 45 cycles each of 167

168 10 s at 95°C, 15 s at 55°C, and 30 s at 72°C.

Data collection and analysis. Data were presented as numbers with percentages or as means \pm 169 standard deviation (SD), as appropriate. To determine Lumipulse assay's LOD, the MedCalc 170 statistical software (MedCalc Software Ltd, Ostend, Belgium) was used to convert RT-PCR 171 positive detection proportion into a "probability unit" (or "probit"). Lumipulse assay's results were 172 173 categorized as positive, gray-zone positive, or negative and, then, compared using a one-way analysis of variance (ANOVA) with the Tukey's multiple-comparison test. For Lumipulse assay's 174 or subgenomic RNA assay's results, differences between a priori established groups were assessed 175 176 using the chi-square test or the Student's t-test, as appropriate. Percent agreement values, with their respective confidence intervals (CIs), were calculated comparing Lumipulse assay's or subgenomic 177 RNA assay's results with those obtained by the reference method (i.e., genomic RNA RT-PCR 178 assay). Correlation between antigen levels (as determined by the Lumipulse assay) and Ct values 179 (as determined by the reference method) was assessed using the Spearman's correlation coefficient. 180

- 181 Statistical analysis was conducted using Stata 15 (StataCorp, College Station, TX) or GraphPad
- 182 Prism 7 (GraphPad Software, San Diego, CA) software. P < 0.05 was considered statistically
- 183 significant.

185 **RESULTS**

SARS-CoV-2 antigen (Lumipulse assay) versus genomic or subgenomic RNA (RT-PCR assay) testing. First, we determined the analytical capability of the Lumipulse assay, a recently marketed assay for SARS-CoV-2 N protein detection in European countries. As shown in Fig. S1, the LOD was 2.95 TCID₅₀/ml, corresponding to 1.2×10^4 SARS-CoV-2 RNA copies/ml, at 95% detection probability. Then, 594 nasopharyngeal swab samples, including RT-PCR positive (n = 194) or negative (n = 400) samples, were tested with the Lumipulse assay.

i) Overall performance. Using SARS-CoV-2 RNA genomic RT-PCR assay as the reference 192 method (Table 1), the Lumipulse assay detected 155 of 194 samples as positive (antigen 193 194 concentration, ≥ 1.34 pg/ml) and 397 of 400 samples as negative (antigen concentration, < 1.34pg/ml). This resulted in a positive percent (PPA) of 79.9% (95% confidence interval (CI), 73.6-195 85.3) and a negative percent agreement (NPA) of 99.3% (95% CI, 97.8-99.8), respectively. Of 155 196 samples, 29 (18.7%) were positive within the gray-zone (antigen concentration, 1.34–10 pg/ml), 197 which defines an antigen positivity extent necessitating to be confirmed by RT-PCR. As depicted in 198 Fig. 1 and detailed in Table 1, we stratified Lumipulse assay's results according to RT-PCR Ct 199 values. Thus, we found significant differences in the mean Ct value \pm SD for 126 samples with 200 antigen-positive results (21.95 ± 6.03) as compared to 29 samples with antigen (gray-zone)-positive 201 202 results (30.85 \pm 3.19) and to 39 samples with antigen-negative results (33.79 \pm 2.39), respectively (ANOVA with Tukey's multiple-comparison test; P < 0.0001 for both comparisons) (Fig. 1). 203 Interestingly, PPAs between Lumipulse assay's and RT-PCR assay's results were 100% for samples 204 205 with Ct values of <18 (n = 38) or 18 - <25 (n = 49) and 92.5% for samples with Ct values of 25 - <30(n = 37). For 31 of 155 samples with Ct values of 30–<35 (n = 23) or 35–40 (n = 8), PPAs dropped 206 to 47.9% and 42.1%, respectively. More interestingly, 24 (82.8%) of 29 antigen (gray zone)-207 positive results regarded samples with Ct values ranging from 25 to 35, whereas three (100%) of 208

three antigen (gray zone)-positive results regarded (antigen false-positive) samples with Ct values
>40.

ii) Performance by different testing groups. Table 2 shows the results of 194 antigen-positive 211 samples—overall described in Table 1—stratified by the diagnostic (n = 69), screening (n = 53), or 212 monitoring (n = 72) groups of testing for 194 patients with laboratory-confirmed COVID-19 213 diagnosis. Only for the monitoring group, samples used in the study were not the same as those at 214 the COVID-19 diagnosis time; thus, this group included COVID-19 patients who were tested 215 during the course of disease. Conversely, 122 patients in the two remaining groups were tested at 216 early disease phases. Table 2 also shows the results from SARS-CoV-2 subgenomic RNA detection 217 218 that was performed in parallel on the 194 samples.

Regarding antigen detection results, PPA with the reference method (i.e., SARS-CoV-2 RNA 219 genomic RT-PCR assay) was 87.0% (95% CI, 76.7-93.9; 60/69 results), 81.1% (95% CI, 68.0-220 221 90.6; 43/53 results), or 72.2% (95% CI, 60.4-82.1; 52/72 results) in diagnostic, screening, and monitoring groups, respectively. Consistent with that shown in Table 1, PPA was 100% for samples 222 with Ct values of <18 or 18–<25 in all three testing groups, and was 94.4%, 80.0%, or 100% for 223 samples with Ct values of 25–<30 in diagnostic, screening, and monitoring groups, respectively. 224 225 Regarding subgenomic RNA detection results, PPA with the reference method was 63.8% (95% CI, 226 51.3-75.0; 44/69 results), 62.3% (95% CI, 47.9-75.2; 33/53 results), or 33.3% (95% CI, 22.7-45.4; 24/72 results) in diagnostic, screening, and monitoring groups, respectively. Unlike antigen 227 detection results, PPAs for samples with Ct values of <18 or 18-<25 were, respectively, 86.7% and 228 229 100% in the diagnostic group, 100% and 94.1% in the screening group, and 100% and 83.3% in the monitoring group. Interestingly, in all three groups, PPAs dropped to 55.6%, 20.0%, or 41.7% for 230 samples with Ct values of 25-<30, and reached 0% for almost all samples with Ct values of 30-<35 231 or 35-40, respectively. A chi-square test analysis was conducted to compare PPAs between antigen 232 and subgenomic-RNA detections among the three testing groups, and this analysis revealed 233

significant differences for the samples overall (P = 0.002, P = 0.03, and P < 0.001, respectively) or the samples with Ct values ranging from 25–<30 or 35–40 (P < 0.05 for all comparisons).

iii) Correlation between antigen levels and RT-PCR Ct values. To corroborate these findings, 236 we assessed antigen levels in relation with the SARS-CoV-2 viral load expressed as RT-PCR Ct 237 values. A Spearman's correlation analysis was conducted for all 194 samples that tested positive 238 with the RT-PCR assay, which were analyzed according to aforementioned testing groups (i.e., 239 240 diagnostic, screening, and monitoring). As shown in Fig. 2, we found a significant (negative) association between antigen levels and Ct values in either diagnostic (Spearman's $\rho = -0.82$; P 241 <0.0001), monitoring (Spearman's $\rho = -0.76$; P <0.0001), or screening (Spearman's $\rho = -0.72$; P 242 243 <0.0001) groups. As it can see, association was relatively stronger in the diagnostic group and less strong in the screening group. 244

Relationship between SARS-CoV-2 antigen and subgenomic RNA. To investigate this issue, we 245 analyzed the characteristics of 194 antigen-positive or -negative samples according to the presence 246 (n = 101) or absence (n = 93) of subgenomic RNA. As shown in Table 3, all 101 samples with a 247 subgenomic RNA positive result had a Lumipulse assay's antigen positive result, whereas only 54 248 (58.1%) of remaining 93 samples had a Lumipulse assay's antigen positive result. Samples in the 249 subgenomic RNA-positive group had a mean Ct value ± SD—at the RT-PCR assay for genomic 250 251 RNA—that did not significantly differ from that of samples in the subgenomic RNA-negative group $(20.3 \pm 4.8 \text{ versus } 29.9 \pm 4.8; \text{ Student's t-test; } P = 0.43)$. Conversely, the time from COVID-19 252 diagnosis to testing (mean days \pm SD) for samples in the subgenomic RNA-positive group 253 significantly differed from the time for samples in the subgenomic RNA-negative group (1.6 ± 3.3) 254 versus 6.1 ± 7.0 ; Student's *t*-test; *P* < 0.001). 255

257 **DISCUSSION**

Taking advantage of antigen tests used to detect infection with viruses other than SARS-CoV-2 258 (16), diagnostics of COVID-19 quickly moved to use non-molecular (i.e., non-RT-PCR) laboratory 259 tests, including the Lumipulse assay (5). Unlike point-of-care antigen test formats (17), Lumipulse 260 assay employs a chemiluminescence-based SARS-CoV-2 antigen quantification (6), which should 261 enhance the test sensitivity to diagnose SARS-CoV-2 infection. To evaluate the Lumipulse assay, 262 we used RT-PCR as the best available comparator method (1), and we showed that the Lumipulse 263 assay had PPA (sensitivity) and NPA (specificity) of ~80% and 99%, respectively. Consequently, 264 the number of false-positive and-negative results driven by these metrics was 39 (among 194 RT-265 266 PCR positive results) and 3 (among 400 RT-PCR negative results), respectively (Table 1). As the Lumipulse assay returns positive results as positive (>10 to 5000 pg/ml) or gray-zone positive 267 (>1.34 to 10 pg/ml), it is worthy to note that all the three false-positive results fell within the gray-268 269 zone range. These results would have been confirmed by RT-PCR if antigen testing had been performed as a frontline diagnostic method at the study time. 270

In our hands, Lumipulse assay met the minimum performance requirements of $\geq 80\%$ sensitivity 271 and $\geq 97\%$ specificity for rapid antigen tests as established by the World Health Organization 272 273 (https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-274 to-support-response-to-the-covid-19-pandemic-v.0.1) and, later, agreed by the ECDC (5). Additionally, we showed that the Lumipulse assay's sensitivity increased from ~93% to 100% with 275 samples that displayed RT-PCR Ct values below 25–30. As a reflection of high viral load, these 276 277 values are likely associated with an infectious SARS-CoV-2, contrasting higher Ct values (>30 to 40) that, instead, are likely associated with a non-infectious SARS-CoV-2 (14). A manner for 278 279 appraising the apparently low performance of the Lumipulse assay as compared to RT-PCR (i.e., ≥90% sensitivity [https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-280 priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1]), it was to assess the 281

Lumipulse assay's results with respect to the results of SARS-CoV-2 subgenomic RNA assay (14), 282 which was performed on the samples concomitantly tested for SARS-CoV-2 antigen. Thus, among 283 194 (SARS-CoV-2 genomic RNA) RT-PCR positive samples, 101 (52.1%) samples had positive 284 results for subgenomic RNA (and antigen), with 82 (94.3%) of 87 antigen-positive samples having 285 RT-PCR Ct values below 18–25 (Tables 2 and 3). Importantly, 54 of 93 samples negative at the 286 subgenomic RNA assay but positive at the Lumipulse antigen assay included samples from patients 287 who were tested 6.1 \pm 7.0 days after COVID-19 diagnosis (Table 3), suggesting that SARS-CoV-2 288 antigen may be longer detected than SARS-CoV-2 subgenomic RNA. Consistent with these 289 findings, 101 aforementioned samples were from patients who were tested 1.6 ± 3.3 days after 290 291 COVID-19 diagnosis (Table 3), suggesting that SARS-CoV-2 antigen may indicate active infection. It should be recalled that SARS-CoV-2 virions do not contain subgenomic RNA-i.e., RNA 292 replicative forms thought to encode the structural spike (S), E, membrane (M), or N virus 293 294 proteins—whereas subgenomic RNA is part of cellular membrane vesicles and thereby relatively stable (15). Thus, antigen and subgenomic RNA represent two virus biology entities worthy of 295 investigation in clinical samples (7, 18, 19), especially in situations of prolonged (genomic RNA) 296 RT-PCR positivity implying infectious virus shedding (15). 297

In an attempt to appraise fully Lumipulse assay's performance, we analyzed 194 RT-PCR positive 298 299 samples stratified by groups of testing (Table 2). This stratification allowed us to assess the accuracy of the Lumipulse assay to determine if a person presenting in the (primary or secondary 300 care) hospital or the community has SARS-CoV-2 infection. Therefore, we included 194 adults 301 302 suspected of (n = 69) or screened for (n = 53) SARS-CoV-2 infection or monitored for confirmed COVID-19 (n = 72) in diagnostic, screening, or monitoring groups, respectively. We found that the 303 Lumipulse assay worked well, and almost equally, in all three testing groups, with 60 (diagnostic 304 group), 43 (screening group), or 52 (monitoring group) samples being positive. Expectedly, the 305 subgenomic RNA assay yielded positive results in 44 (diagnostic group), 33 (screening group), or 306

24 (monitoring group) samples. Of note, lowest sample positivity rates were seen in the monitoring group with both Lumipulse (52/72 samples, 72.2%) and subgenomic RNA (24/72 samples, 33.3%) assays. These findings concur with the idea that SARS-CoV-2 antigen or, particularly, subgenomic RNA results are likely to be less positive in monitoring scenarios where positive results for genomic RNA are, instead, indicative of prolonged SARS-CoV-2 shedding (15). Accordingly, in our monitoring group, the time from COVID-19 diagnosis to testing was longer (up to 32 days) than in diagnostic or screening groups (0 days).

To the best of our knowledge, this is to date the largest clinical study evaluating the Lumipulse 314 assay. Compared to previous studies (6, 7), our set of tested nasopharyngeal swab samples is not 315 316 only wider but also uncharted-we included 594 individuals' samples from testing scenarios with different pretest probability that, in turn, reflected different clinical situations. Nonetheless, our 317 findings agreed with those by Hirotsu et al. (6) showing that the SARS-CoV-2 antigen levels 318 319 declined in consecutively collected samples of seven patients from the time of their hospital admission to discharge. Therefore, the finding that antigen positivity rates varied according to 320 whether samples were in a diagnostic/screening rather than in a monitoring scenario reinforces the 321 hypothesis raised by Hirotsu et al. that antigen testing could be also useful to identify patients in the 322 early or late phase of SARS-CoV-2 infection (6). In an evaluations' review of five antigen tests 323 324 (four commercial and one in-house) by Dinnes et al. (17), average sensitivity was 56.2% (95% CI, 29.5 to 79.8%) and average specificity was 99.5% (95% CI 98.1 to 99.9%) based on five studies 325 with 943 samples (596 were confirmed SARS-CoV-2 samples). However, the sensitivity varied 326 327 considerably across studies (from 0% to 94%), causing uncertainty about how useful antigen tests are in clinical practice (17). To enhance the applicability of our Lumipulse assay's results, we 328 determined the assay's analytical sensitivity (Fig. S1) before sample testing to ensure that the 329 assay's LOD was equivalent to 10^4 viral genomic copies/ml, which is the desirable limit 330 acknowledged to date (https://www.who.int/publications/m/item/covid-19-target-product-profiles-331

for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1). 332 Furthermore, we limited oversampling of samples with laboratory-confirmed SARS-CoV-2 infection, which 333 accounted for the high risk of bias affecting patient selection in many published studies (17). 334 Stratifying our study participants by days from the symptom onset (5) was impracticable for us. 335 However, we compensated for this limitation by including testing groups that were comparable for 336 size (~60 RT-PCR positive samples per group), and we assumed that RT-PCR negative samples 337 were almost equally distributed across testing groups. 338

To summarize, our results show that Lumipulse assay's performance was satisfactory, confirming the current view about antigen-based laboratory testing for SARS-CoV-2 detection. In particular, the Lumipulse assay was highly sensitive to detect SARS-CoV-2 antigen in samples with low RT-PCR Ct values (<25) by overall or different testing scenarios. While Ct values >25 might not correspond to situations with active SARS-CoV-2 infection and/or infectivity, a strategy of repeated testing can maximize the Lumipulse assay's performance and thereby reduce consequences of falsenegative results.

346 ACKNOWLEDGEMENTS

The authors are grateful to the Reale Group and the Fondazione Valentino Garavani & Giancarlo Giammetti for providing financial support to the COVID-19 Research at the FPG (<u>Fondazione</u> <u>Policlinico Universitario A. Gemelli IRCCS</u>) of Rome (Italy), or with the Italian Health Ministry for providing funds to the INMI (<u>Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani</u> IRCCS) of Rome (Italy).

352 We thank Franziska Lohmeyer for English revision of the manuscript.

354 **REFERENCES**

- 355 1. Brooks ZC, Das S. 2020. COVID-19 testing. Am J Clin Pathol 154:575–584.
 356 https://doi.org/10.1093/ajcp/aqaa141.
- Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S,
 Yansouni CP. 2020. Diagnostic testing for severe acute respiratory syndrome–related
 coronavirus-2: a narrative review. Ann Intern Med M20-1301. https//doi.org/10.7326/M20 1301.
- 361 3. Mak GC, Lau SS, Wong KK, Chow NL, Lau CS, Lam ET, Chan RC, Tsang DN. 2020.
 362 Analytical sensitivity and clinical sensitivity of the three rapid antigen detection kits for
 363 detection of SARS-CoV-2 virus. J Clin Virol 133:104684.
 364 https://doi.org/10.1016/j.jcv.2020.104684.
- Ogawa T, Fukumori T, Nishihara Y, Sekine T, Okuda N, Nishimura T, Fujikura H, Hirai N,
 Imakita N, Kasahara K. 2020. Another false-positive problem for a SARS-CoV-2 antigen
 test in Japan. J Clin Virol 131:104612. https://doi.org/10.1016/j.jcv.2020.104612.
- 5. European Centre for Disease Prevention and Control (ECDC). Options for the use of rapid
 antigen tests for COVID-19 in the EU/EEA and the UK. 19 November 2020. ECDC:
 Stockholm; 2020.
- 6. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, Sueki H,
 Hayakawa M, Mochizuki H, Tsutsui T, Kakizaki Y, Miyashita Y, Yagi S, Kojima S, Omata
 M. 2020. Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with
 quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially
 followed patients. Int J Infect Dis 99:397–402. https://doi.org/10.1016/j.ijid.2020.08.029.
- 376 7. Hirotsu Y, Maejima M, Shibusawa M, Amemiya K, Nagakubo Y, Hosaka K, Sueki H,
 377 Hayakawa M, Mochizuki H, Tsutsui T, Kakizaki Y, Miyashita Y, Omata M. 2020. Analysis
 378 of a persistent viral shedding patient infected with SARS-CoV-2 by RT-qPCR, FilmArray

- 379 Respiratory Panel v2.1, and antigen detection. J Infect Chemother Oct 29:S1341380 321X(20)30396-2. https://doi.org/10.1016/j.jiac.2020.10.026. Epub ahead of print.
- Liotti FM, Menchinelli G, Marchetti S, Morandotti GA, Sanguinetti M, Posteraro B, Cattani
 P. 2020. Evaluation of three commercial assays for SARS-CoV-2 molecular detection in
 upper respiratory tract samples. Eur J Clin Microbiol Infect Dis Sep 4:1–9.
 https://doi.org/10.1007/s10096-020-04025-0. Epub ahead of print.
- 385
 9. Liotti FM, Menchinelli G, Lalle E, Palucci I, Marchetti S, Colavita F, La Sorda M, Sberna
 386
 G, Bordi L, Sanguinetti M, Cattani P, Capobianchi MR, Posteraro B. 2020. Performance of
 a novel diagnostic assay for rapid SARS-CoV-2 antigen detection in nasopharynx samples.
- 388
 Clin
 Microbiol
 Infect
 Sep
 23:S1198-743X(20)30583-8.

 389
 https://doi.org/10.1016/j.cmi.2020.09.030. Epub ahead of print.
- 10. Poljak M, Korva M, Knap Gašper N, Fujs Komloš K, Sagadin M, Uršič T, Avšič Županc T,
 Petrovec M. 2020. Clinical evaluation of the Cobas SARS-CoV-2 test and a diagnostic
 platform switch during 48 hours in the midst of the COVID-19 pandemic. J Clin Microbiol
 58:e00599-20. https://doi.org/10.1128/JCM.00599-20.
- 11. Procop GW, Brock JE, Reineks EZ, Shrestha NK, Demkowicz R, Cook E, Ababneh E,
 Harrington SM. A 2021. Comparison of five SARS-CoV-2 molecular assays with clinical
 correlations. Am J Clin Pathol 155:69–78. https://doi.org/10.1093/ajcp/aqaa181.
- 12. Liotti FM, Menchinelli G, Marchetti S, Morandotti GA, Sanguinetti M, Posteraro B, Cattani
 P. 2020. Evaluating the newly developed BioFire COVID-19 test for SARS-CoV-2
 molecular detection. Clin Microbiol Infect 26:1699–1700.
 https://doi.org/10.1016/j.cmi.2020.07.026.
- 401 13. Liotti FM, Menchinelli G, Marchetti S, Posteraro B, Landi F, Sanguinetti M, Cattani P.
 402 2020. Assessment of SARS-CoV-2 RNA test results among patients who recovered from

403	COVID-19	with	prior	negative	results.	JAMA	Intern	Med	Nov	12:e207570.
404	https://doi.or	rg/10.1	001/jan	nainternme	d.2020.75	70. Epub	ahead of	f print.		

- 405 14. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,
- 406 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann
- 407 R, Zwirglmaier K, Drosten C, Wendtner C. 2020. Virological assessment of hospitalized
- 408 patients with COVID-2019. Nature 581:465–469. https://doi.org/10.1038/s41586-020-2196-

409

x.

- 410 15. Alexandersen S, Chamings A, Bhatta TR. 2020. SARS-CoV-2 genomic and subgenomic
 411 RNAs in diagnostic samples are not an indicator of active replication. Nat Commun 2020
 412 11:6059. https://doi.org/10.1038/s41467-020-19883-7.
- 413 16. Clerc O, Greub G. 2010. Routine use of point-of-care tests: usefulness and application in
 414 clinical microbiology. Clin Microbiol Infect 2010 16:1054–1061.
 415 https://doi.org/10.1111/j.1469-0691.2010.03281.x.
- 17. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, Emperador D,
 Takwoingi Y, Cunningham J, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price
 MJ, Taylor-Phillips S, Hooft L, Leeflang MM, Spijker R, Van den Bruel A; Cochrane
 COVID-19 Diagnostic Test Accuracy Group. 2020. Rapid, point-of-care antigen and
 molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev
 8:CD013705. https://doi.org/10.1002/14651858.CD013705.
- 18. Rodríguez-Grande C, Adán-Jiménez J, Catalán P, Alcalá L, Estévez A, Muñoz P, PérezLago L, de Viedma DG; Gregorio Marañón Microbiology-ID COVID 19 Study Group.
 2020. Inference of active viral replication in cases with sustained positive RT-PCRs for
 SARS-CoV-2. J Clin Microbiol Nov 25:JCM.02277-20.
 https://doi.org/10.1128/JCM.02277-20. Epub ahead of print.

19. Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, Barbian K, 427 Judson SD, Fischer ER, Martens C, Bowden TA, de Wit E, Riedo FX, Munster VJ. 2020. 428 Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic 429 Immunocompromised Individual with Cancer. Cell 183:1901-1912.e9. doi: 430 10.1016/j.cell.2020.10.049. 431

433 **FIGURE LEGENDS**

FIG 1 Distribution of Lumipulse assay's results according to RT-PCR assay's Ct values in 194 nasopharyngeal samples. Results are presented as positive (>10–5000), gray-zone positive (1.34–10 pg/ml), or negative (<1.34 pg/ml), respectively. In each violin plot, solid line indicates the mean Ct value (21.95, 30.85, and 33.79, respectively) and the area between dotted lines indicates the standard deviation value (6.03, 3.19, and 2.39, respectively). Asterisks indicate statistically significance (P <0.0001) between result groups, as established using a one-way analysis of variance (ANOVA) with the Tukey's multiple-comparison test.

FIG 2 Correlation between the SARS-CoV-2 antigen levels quantified by the Lumipulse assay and the SARS-CoV-2 genomic RNA Ct values obtained with the RT-PCR assay. Analysis was separately conducted for (a) diagnostic, (b) screening, and (c) monitoring testing groups. Antigen concentration is expressed as log₁₀ pg/ml. Concentrations of <1.34 pg/ml, 1.34 to 10 pg/ml, and >10 pg/ml were used to interpret Lumipulse assay's antigen results as negative, gray-zone positive, or positive, respectively.

FIG S1 Probit analysis to calculate the limit of detection (LOD) of the Lumipulse G SARS-CoV-2 447 Ag assay. In this analysis, input was the numbers of samples with positive detection, which were 448 obtained with Vero E6 cell-cultured SARS-CoV-2 (INMI-1 strain) tested in replicates at a 449 concentration range of 1.0×10^5 50% tissue culture infective dose (TCID₅₀)/ml (4.0×10^8 RNA 450 copies/ml) to 1.0 TCID₅₀/ml (4.0×10^3 RNA copies/ml). The output was the Lumipulse assay's 451 LOD, which was equivalent to a value of 0.47 log₁₀ TCID₅₀/ml (otherwise expressed as 2.95 452 TCID₅₀/ml) corresponding to 4.07 log₁₀ RNA copies/ml (otherwise expressed as 1.2×10^4 453 copies/ml). 454

TABLE 1. Comparison of Lumipulse assay results with the RT-PCR assay results stratified by Ct values for SARS-CoV-2 detection

RT-PCR assay ^a	Lumipulse assay ^b	
	No. of positive (including gray-zone positive)	
Ct values (no. of results)	results	Percent agreement (95% confidence interval)
≤40 (194)	155 (29)	79.9 (73.6–85.3)
<18 (38)	38 (0)	100.0 (90.7–100.0)
18-<25 (49)	49 (1)	100.0 (92.7–100.0)
25-<30 (40)	37 (10)	92.5 (79.6–98.4)
30-<35 (48)	23 (14)	47.9 (33.3–62.8)
35-40 (19)	8 (4)	42.1 (20.3–66.5)
>40 (400)	3 (3)	99.3 (97.8–99.8)

Abbreviations: RT-PCR, real-time reverse-transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Ct, cycle threshold.

^a SARS-CoV-2 RT-PCR testing was performed on 594 individuals' nasopharyngeal swab samples. A positive result (i.e., a Ct \leq 40) for at least one of two viral targets with the Seegene Allplex 2019-nCoV (nucleocapsid [N] and RdRP [RNA-dependent RNA polymerase]), the DiaSorin Simplexa COVID-19 Direct (S [spike] and ORF1ab [open reading frame 1ab]), or the Roche Diagnostics

Cobas SARS-CoV-2 Test (E [envelope] and ORF1a) assays indicated the presence of SARS-CoV-2 RNA in individual's nasopharyngeal swab samples (n = 194). Samples with a Ct >40 for the mentioned genes were considered negative (n = 400). ^b SARS-CoV-2 antigen testing was performed on 594 individuals' nasopharyngeal swab samples with the Lumipulse G SARS-CoV-2 Ag assay. Using the manufacturer's cutoff of 1.34 pg/ml, results were interpreted as gray-zone positive or positive when antigen

concentrations were 1.34–10 and >10–5000 pg/ml, respectively.

TABLE 2. Positive detections of Lumipulse antigen and subgenomic RNA compared with those of RT-PCR for SARS-CoV-2 in different testing groups^a

Ct values (no. of	Lumipulse antigen dete	ction ^b	Subgenomic RNA det	D l d	
results)	results) No. of results		No. of results	Percent agreement	- P value
	(including gray-zone	(95% confidence		(95% confidence	
	results)	interval)		interval)	
Diagnostic group					
<18 (15)	15 (0)	100.0 (78.2-100.0)	13	86.7 (59.5–98.3)	0.14
18-<25 (20)	20(0)	100.0 (83.2-100.0)	20	100.0 (83.2–100.0)	NA
25-<30 (18)	17 (1)	94.4 (72.7–99.9)	10	55.6 (30.8-78.5)	0.009
30-<35 (10)	6 (5)	60.0 (26.2-87.8)	0	0.0 (0.0-30.8)	0.003
35-40 (6)	2 (0)	33.3 (4.3–77.7)	1	16.7 (0.4–64.1)	0.52
All (69)	60 (6)	87.0 (76.7–93.9)	44	63.8 (51.3-75.0)	0.002
Screening group					
<18 (15)	15	100.0 (78.2-100.0)	15	100.0 (78.2–100.0)	NA
18-<25 (17)	17	100.0 (80.5-100.0)	16	94.1 (71.3–99.9)	0.30
25-<30 (10)	8 (5)	80.0 (44.4–97.5)	2	20.0 (2.5-55.6)	0.007
30-<35 (8)	3 (2)	38.0 (8.5-75.5)	0	0.0 (0.0-36.9)	0.05
35-40 (3)	0	0.0 (0.0-70.6)	0	0.0 (0.0-70.6)	NA
All (53)	43 (7)	81.1 (68.0-90.6)	33	62.3 (47.9–75.2)	0.03
Monitoring group					
<18 (8)	8	100.0 (63.1-100.0)	8	100.0 (63.1–100.0)	NA
18-<25 (12)	12(1)	100.0 (73.5-100.0)	10	83.3 (51.6–97.9)	0.13
25-<30 (12)	12 (4)	100.0 (73.5-100.0)	5	41.7 (15.2–72.3)	0.002
30-<35 (30)	14 (7)	46.7 (28.3-65.7)	1	3.3 (0.1–17.2)	< 0.001
35-40 (10)	6 (4)	60.0 (26.2-87.8)	0	0.0 (0.0-30.8)	0.003
All (72)	52 (16)	72.2 (60.4-82.1)	24	33.3 (22.7–45.4)	< 0.001

Results according to indicated RT-PCR Ct values for:

Abbreviations: RT-PCR, real-time reverse-transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Ct, cycle threshold; NA, not applicable.

^a Groups were established according to the Centers for Disease Control and Prevention (CDC) definitions for testing settings (https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html#anchor_1597523027400), and were further stratified by viral load (i.e., Ct values) as indicated.
 ^b SARS-CoV-2 antigen was detected in nasopharyngeal swab samples of groups' individuals by the Lumipulse G SARS-CoV-2 Ag assay,

^o SARS-CoV-2 antigen was detected in nasopharyngeal swab samples of groups' individuals by the Lumipulse G SARS-CoV-2 Ag assay, which provides a 0.01–5000 pg/ml measurement range. Using the manufacturer's cutoff of 1.34 pg/ml, results were expressed as negative, gray-zone positive, or positive when antigen concentrations in the samples were <1.34, 1.34–10, or >10–5000 pg/ml, respectively. Samples with antigen concentrations above 5000 pg/ml were rounded to 5000 pg/ml for convenience reasons.

^c SARS-CoV-2 subgenomic RNA was detected in nasopharyngeal swab samples of groups' individuals by in-house RT-PCR assay for the presence of replicative (E gene) RNA (Liotti, 2020c).

^d For comparisons between percent agreement rates.

	Samples with a subge	enomic RNA positive	Samples with a subg			
Characteristic ^b	result $(n = 101)$ group	ped as	negative result $(n = 2)$	D		
	RT-PCR	RT-PCR	RT-PCR	RT-PCR	<i>i</i>	
	positive/Antigen	positive/Antigen	positive/Antigen	positive/Antigen	value	
	positive $(n = 101)$	negative $(n = 0)$	positive $(n = 54)$	negative $(n = 39)$		
RT-PCR Ct, mean value	20.3 ± 4.8	NA^d	29.9 ± 4.8	33.8 ± 2.4	0.43	
± SD						
Testing from COVID-19	1.6 ± 3.3	NA^d	6.1 ± 7.0	7.7 ± 8.6	<0.001	
diagnosis, mean days ±						
SD						

TABLE 3. Characteristics of 194 RT-PCR positive samples that tested positive or negative for the presence of SARS-CoV-2 subgenomic RNA^a

^a All samples were from diagnostic (n = 59), screening (n = 63), or monitoring (n = 72) testing groups (see Table 2). Testing for SARS-CoV-2 subgenomic RNA was performed using an in-house RT-PCR assay to assess the presence of replicative (E gene) RNA, as previously described (Liotti, 2020c). ^b The time period between SARS-CoV-2 RT-PCR (to which Ct values refer) used to diagnose COVID-19 and testing for SARS-CoV-2

^b The time period between SARS-CoV-2 RT-PCR (to which Ct values refer) used to diagnose COVID-19 and testing for SARS-CoV-2 subgenomic RNA (and antigen) ranged from 0 days in the diagnostic or screening groups to 32 days in the monitoring group. Only in the last group, consequently, two temporally different samples were tested.

^c For comparisons between the RT-PCR positive/Antigen positive groups herein listed.

^d NA, not applicable.



